BUSINESS OVERVIEW
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.
We unite AI with cutting-edge science to discover life-changing medicines.
Through the combined capabilities of its AI platform, its scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods.
The Benevolent Platform™ powers BenevolentAI’s in-house drug pipeline and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.
Financial calendar
|
September 2023
Interim Results for the six months ended 30 June 2023
|
EMAIL ALERTS
Get alerts for our announcements
Investor events, conference attendance and annual reporting.